SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Hands reach out to each other. Handshake. Halftone retro hands. Body parts cut out of newspaper. Hands tied with thread. Shaking hands. Make a deal. Successful agreement. Modern collage
Drug discovery
AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal
The ADARx Pharmaceuticals partnership, which could be worth “several billion dollars” in the end, adds to AbbVie’s existing work in the space after the $1.4 billion acquisition of Aliada Therapeutics in October 2024.
May 14, 2025
 · 
2 min read
 · 
Annalee Armstrong
Art 3d banner collage of business people dollar roll cooperation success payment capital profit transaction money corruption.
MASH
GSK Buys Phase III–Ready Liver Drug in Potential $2B Deal To Play in MASH Arena
GSK secures rights to Boston Pharmaceuticals’ efimosfermin alfa, which the pharma plans to develop for fatty liver diseases such as metabolic dysfunction-associated steatohepatitis and alcohol-related liver disease.
May 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Crumpled paper balls fly into a miniature bucket, the concept of searching for new ideas
Lung cancer
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Class Failures
Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck squamous cell carcinoma.
May 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Businessman team walking at a crossroads following the arrows
Arcturus Prunes Early-Stage Pipeline, Leans Into mRNA Therapies
Arcturus is extending its cash runway into 2028 by discontinuing its early-stage vaccine candidates.
May 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Pleasanton, CA, USA - Feb 21, 2024: Exterior view of the headquarters of Roche Molecular Diagnostics (RMD) in Pleasanton, California. F. Hoffmann-La Roche AG is a Swiss pharmaceutical company.
Manufacturing
Roche Continues US Investments With $550M Diagnostics Push in Lilly’s Backyard
Roche envisions its Indianapolis site as a “major hub” for the manufacturing of its continuous glucose monitoring systems. The news comes on the heels of an announced $700 million investment in North Carolina.
May 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter
President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price negotiations; Vinay Prasad to take the helm at the FDA’s Center for Biologics Evaluation and Research; Bayer cuts 2,000 more employees; Eli Lilly’s Zepbound scores again; and the Galapagos story turns again.
May 14, 2025
 · 
2 min read
 · 
Heather McKenzie
Illustration showing large scissors cutting employees in half
Layoffs
The 5 Largest Biopharma Layoffs of Q1 2025: Updated
The number of employees laid off increased year over year during the first quarter. BioSpace recaps the five largest rounds of layoffs, which included BMS and Novartis cuts.
May 13, 2025
 · 
5 min read
 · 
Angela Gabriel
Businessman on a crossroad. Man choosing career. Searching of right path. Decision and brainstorming concept. Flat vector illustration.
C-suite
Galapagos Takes Dramatic U-Turn, Ditching Spinout Plan, Cell Therapy and CEO Stoffels
It’s another wild twist in the story of Galapagos, a company that has been around for more than 25 years but has yet to get a therapy approved.
May 13, 2025
 · 
2 min read
 · 
Annalee Armstrong
Bayer office in Basel, Switzerland
Earnings
Bayer’s Continued Restructuring Claims 2,000 Jobs and Thins Management Layers
Meanwhile, Bayer CEO Bill Anderson said Donald Trump’s Most Favored Nations policy could present an opportunity for European countries to make sure they are also funding their “fair share” of biopharma innovation.
May 13, 2025
 · 
3 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS